Drugs / Andrographis Paniculata
Andrographis Paniculata
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04161404 | Aug → Dec 2019 | — | University of Malaya | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05019326 | Aug 2021 → May 2022 | COVID-19 | Mahidol University | Unknown | No outcome recorded |
| Phase 3 | NCT04196075 | Mar 2018 → Feb 2021 | esophageal squamous cell carcinoma | Chinese University of Hong Kong | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Andrographis paniculata | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04161404 ↗ |
| Known as | Andrographis Herba | “Single lot of Andrographis paniculata (AP) concentrated granules (Andrographis Herba) will be manufactured by Nong's Company Limited under GMP standard” NCT04196075 ↗ |
| Known as | hempedu bumi | “Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia” NCT04161404 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia” NCT04161404 ↗ |
| Route | Oral | “single dose oral administration of Andrographis Paniculata 1000mg, 2000mg and Metformin 1000mg clinical trial” NCT04161404 ↗ |